Read the latest expert‐written articles on recently published manuscripts that make influential contributions to the body of infectious diseases literature.
Fecal microbiota transplantation (FMT) is a widely accepted, safe, and effective treatment for recurrent Clostridium difficile infection (rCDI), but does the cure endure?
Alternative agents are often broader spectrum than ß-lactams, subjecting patients to collateral damage and subsequent selection for resistant organisms and Clostridium difficile.
Many patients with pneumonia are empirically treated with anti-MRSA therapy, leaving antimicrobial stewardship programs faced with the challenge of identifying patients who truly warrant continuation of this therapy.
